新诊断多发性骨髓瘤中动态MRD轨迹的预后意义
该回顾性研究分析231例达≥完全缓解的新诊断多发性骨髓瘤患者的系列MRD结果,发现MRD阴性独立预测更优PFS和OS,持续阴性≥6个月改善OS,≥12个月对PFS和OS均有获益,支持系列MRD监测作为个体化MRD驱动治疗策略的基础。
要点
- MRD阴性独立预测更优PFS(HR=0.222)和OS(HR=0.280)。
- 持续MRD阴性≥12个月对PFS和OS均有预后获益。
- 诱导后未达MRD阴性是转阳后进展的独立危险因素。
核心结论
- 持续MRD阴性具有预后意义,支持系列MRD监测作为NDMM个体化MRD驱动治疗策略的潜在基础。
研究设计与样本
- 回顾性研究,分析231例达≥完全缓解的新诊断多发性骨髓瘤患者的系列MRD结果。
主要发现
- MRD阴性独立预测更优PFS(HR=0.222;95%CI 0.124-0.400,p<0.001)和OS(HR=0.280;95%CI 0.097-0.809,p=0.019)。
- 持续MRD阴性≥6个月改善OS(p<0.001),阴性持续时间≥12个月对PFS和OS均有预后获益(均p<0.001)。
- 晚期MRD转阳(阴性≥12个月后)患者OS与持续阴性者相当(p=0.339)。
- 诊断时循环浆细胞升高(HR=3.761;95%CI 1.225-11.550,p=0.021)、诱导后未达MRD阴性(HR=2.886;95%CI 1.065-7.819,p=0.037)、MRD转阳时异常PC/BMPC%高(HR=4.091;95%CI 1.429-11.701,p=0.009)是转阳后进展的独立危险因素。
临床怎么用
- 对达≥完全缓解的NDMM患者进行系列MRD监测,关注持续阴性时长及转阳时异常PC/BMPC%。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While minimal residual disease (MRD) is a well-recognized prognostic marker in multiple myeloma (MM), the clinical significance of dynamic MRD trajectories and MRD-driven therapies remains incompletely elucidated. This retrospective study analysed serial MRD results from 231 newly diagnosed multiple myeloma (NDMM) patients who achieved ≥ complete remission (CR). MRD negativity independently predicted superior progression-free survival (PFS) (hazard ratio [HR] = 0.222; 95% confidence interval [CI] 0.124-0.400, p < 0.001) and overall survival (OS) (HR = 0.280; 95% CI 0.097-0.809, p = 0.019). Sustaining MRD negativity for ≥6 months improved OS (p < 0.001), while negativity duration ≥12 months conferred dual prognostic benefits for both PFS and OS (both p < 0.001). Patients with late MRD conversion (after ≥12 months of negativity) had OS comparable to those with sustained negativity (p = 0.339). Elevated circulating plasma cell at diagnosis (HR = 3.761; 95% CI 1.225-11.550, p = 0.021), failure to achieve MRD negativity post-induction (HR = 2.886; 95% CI 1.065-7.819, p = 0.037), and a high abnormal PC/BMPC% at MRD conversion (HR = 4.091; 95% CI 1.429-11.701, p = 0.009) were independent risk factors for progression post-conversion. These findings demonstrate the prognostic significance of sustained MRD negativity and support serial MRD monitoring as a potential basis for individualized MRD-driven treatment strategies in NDMM.
引用
- Yu J, Chen Q, Shi M, et al. Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma. Br J Haematol. 2026. PMID: 42481078. doi:10.1111/bjh.70704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。